Objetivo
HIV-1 and AIDS are spreading in Africa and Asia at unprecedented speed. A vaccine against HIV-1/AIDS is urgently needed. Vaccine candidates that show most promise in simian AIDS models are based on a prime-boost strategy, applying naked DNA or alphaviruses as prime and pox viruses as boost. The objectives of the EuroVac- II project are to demonstrate in a phase I trial of humans: firstly the ability of Semliki Forest virus (SFV) to prime anti-HIV immune responses, - compared to the attenuated poxvirus NYVAC -, using a recombinant gp140 protein boost; and secondly the ability of SFV priming, - using DNA priming as benchmark -, to improve the immune responses elicited by NYVAC + rgp140 vaccination. This design will provide conclusions concerning the relative immunogenicity of different prime-boost strategies. The HIV-1 genes used are recovered from a primary isolate belonging to HIV-1 subtype C, the most frequent cause of AIDS worldwide. The choice of genes (gag, pol, nef) other than envelope is based on the frequency of HIV-specific T-cell responses in long-term asymptomatic HIV infected individuals.
Ámbito científico
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural.
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural.
- natural sciencesbiological sciencesmicrobiologyvirology
- natural sciencesbiological sciencesgeneticsDNA
- medical and health sciencesbasic medicineimmunology
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Convocatoria de propuestas
Data not availableRégimen de financiación
DEM - Demonstration contractsCoordinador
171 77 Stockholm
Suecia